Syndesi Therapeutics Acquisition, Valuation, Funding & Investors

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.

Biossil is an applied AI drug discovery platform that develops specialized treatments for individual patients.

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Orca Bio is a Menlo Park-headquartered clinical-stage cell therapy company engineering allogeneic T-cell products for blood cancers and autoimmune diseases. Its OrcaTropic platform purifies precise cell doses from donors, advancing phase 1/2 trials for lymphoma and multiple sclerosis at centers like Stanford. Orca Bio targets over 100 indications with automated manufacturing.

Profluent Bio is a South San Francisco-headquartered biotechnology company pioneering AI-driven protein design to create functional proteins for therapeutics and industrial applications. Founded in 2022, it leverages large language models adapted for biology to engineer proteins that outperform natural sequences in binding affinity and stability.

Tchaikapharma Highquality Medicines AD is engaged in the business of manufacturing and selling pharmaceuticals in Bulgaria. The company specializes in both generic and in-licensed manufacturing. The company has medicines for Anaesthetics, Nervous system, Oncology, Anti-Inflammatory and Anti-Rheumatic, Antibiotics, Digestive system, diabetes and metabolism, and Respiratory system. The company generates all of its revenue from the sale of medicines. Geographically, the company generates the majority of its revenue from Bulgaria.

Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.

Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.

Savara is a publicly traded clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor being developed for autoimmune pulmonary alveolar proteinosis, a disorder in which material accumulates in the lungs and impairs breathing. The company conducts clinical development and regulatory work rather than selling a commercial respiratory product. Savara trades on Nasdaq and is financed through the public capital markets and research partnerships.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.

Oscotec Inc is engaged in drug discovery for osteoporosis, arthritis, periodontal, dental health and cancer diseases.

TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Symbiotec Pharmalab makes steroid active ingredients and intermediates from plant-based raw materials. It sells to pharma makers in India and overseas. Based in Indore.